[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616837":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":39,"centralContacts":44,"locations":51,"responsibleParty":72,"collaborators":28,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":28,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":28,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":54,"whyStopped":28,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","OTHER",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: Mirabegron","EXPERIMENTAL","Patients receive Mirabegron 50 mg daily.",[13],"Drug: Mirabegron",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B: Tamsulosin","ACTIVE_COMPARATOR","Patients receive Tamsulosin 0.4 mg daily.",[19],"Drug: Tamsulosin",{"label":21,"type":10,"description":22,"interventionNames":23},"Group C: Combination","Patients receive Mirabegron 50mg and Tamsulosin 0.4mg daily.",[13,19],{"label":25,"type":26,"description":27,"interventionNames":28},"Group D: Standard of Care","NO_INTERVENTION","Patients receive standard conservative management (symptomatic control with NSAIDs\u002Fanalgesics on demand).",null,[30,35],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":28},"DRUG","Mirabegron","50 mg tablet orally once daily.",[9,21],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":28},"Tamsulosin","0.4 mg tablet orally once daily.",[15,21],[40],{"name":41,"affiliation":42,"role":43},"Shu-Yu Wu, MD","Taichung Tzu Chi Hospital","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Shu-Yu Wu, Doctor of Medicine","CONTACT","+886-2-6628-9779","60146","nobookrain2014@gmail.com",[52],{"facility":53,"status":54,"city":55,"state":28,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Taipei Tzu Chi Hospital","RECRUITING","New Taipei City","231","Taiwan","TW",{"type":60,"coordinates":61},"Point",[62,63],121.45703,25.06199,{"lat":63,"lon":62},[66,67,71],{"name":41,"role":47,"phone":48,"phoneExt":49,"email":50},{"name":68,"role":47,"phone":48,"phoneExt":69,"email":70},"WAN-LING YOUNG, Bachelor of Science in Nursing","64124","lisayoung1345@gmail.com",{"name":41,"role":43,"phone":28,"phoneExt":28,"email":28},{"type":43,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Shu-Yu Wu","Attending Physician","100616837","phase-4-comparison-of-mirabegron-and-tamsulosin-for-ureteral-stone-expulsion-100616837",false,"NCT07310797","Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion","A Randomized Controlled Trial Comparing Mirabegron and Tamsulosin for Ureteral Stone Expulsion and Clinical Symptom Improvement","Inclusion Criteria:\n\n1. Age and Sex: Adult patients aged 18 to 75 years, inclusive of both males and females.\n2. Diagnosis: Unilateral ureteral stone confirmed by Computed Tomography (CT), Renal Sonography, or Kidney-Ureter-Bladder (KUB) radiography.\n3. Stone Characteristics: Stone size between 4 mm and 10 mm; located in the upper (proximal), middle, or lower (distal) ureter.\n4. Symptoms and Renal Function: Presence of renal colic or hematuria, with no severe renal insufficiency (eGFR \\> 60 mL\u002Fmin\u002F1.73m²).\n\nExclusion Criteria:\n\n1. Urinary tract infection (UTI).\n2. Multiple or bilateral ureteral stones.\n3. Ureteral stones not visible on KUB radiography (radiolucent stones).\n4. Pregnant or lactating women.\n5. Severe hydronephrosis.\n6. Renal insufficiency (defined as eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² or Serum Creatinine \\> 2 mg\u002FdL).\n7. Uncontrolled hypertension or major cardiovascular disease.\n8. Patients who refuse Medical Expulsive Therapy (MET).","ALL","18 Years","75 Years",{"count":86,"type":87},500,"ESTIMATED","INTERVENTIONAL",[90],"PHASE4","This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.",[93],"Ureteral Calculi",[32,36,95],"Medical Expulsive Therapy","2026-06-04",{"date":98,"type":99},"2026-06-08","ACTUAL",{"date":101,"type":99},"2026-02-13",{"date":103,"type":87},"2030-12-31",{"name":5,"class":6},1]